Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis.

NCT00540618 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00540618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00540618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis.
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2001
Completion date
July 31, 2003
Enrollment
420 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis